Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04676529 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
A Phase 1 study, sponsored by Syntara.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT04676529 is a Phase 1 study that has completed, run by Syntara. The registered enrollment target is 43 participants.
The verdict
NCT04676529, a Phase 1 study, has completed, sponsored by Syntara.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study will be an open-label phase 1/2a study to evaluate the safety and tolerability of PXS-5505 in patients with primary, postpolycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis.
Interventions
- DRUG PXS-5505
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2021-02-18 |
| Est. Completion | 2025-07-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04676529
The ClinicalTrials.gov registry entry for NCT04676529 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syntara, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PXS-5505 is the first listed.
NCT04676529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04676529 about?
NCT04676529 is a clinical study titled "Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis". This study will be an open-label phase 1/2a study to evaluate the safety and tolerability of PXS-5505 in patients with primary, postpolycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis.
What is the current status of trial NCT04676529?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2021-02-18. Estimated completion is 2025-07-09.
What interventions are being tested in trial NCT04676529?
The interventions under investigation include: PXS-5505 (DRUG).
Who is sponsoring clinical trial NCT04676529?
This trial is sponsored by Syntara, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.